PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

1 day ago · Preliminary, unaudited revenue for the fourth quarter of 2024 is expected to be approximately $39.2 million compared with $58.4 million in the prior-year period. Preliminary …

$39
OFF

PacBio Announces Preliminary Fourth Quarter And Full Year Revenue

2 weeks from now

1 day ago · Preliminary, unaudited revenue for the fourth quarter of 2024 is expected to be approximately $39.2 million compared with $58.4 million in the prior-year period. Preliminary …

pacb.com

$39
OFF

PacBio Announces Preliminary Q4 Revenue Of $39.2M

2 weeks from now

22 hours ago · PacBio (NASDAQ:PACB) on Tuesday announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154 million, representing …

seekingalpha.com

$39
OFF

PacBio Announces Preliminary Q4 Revenue Of $39.2M - MSN

2 weeks from now

PacBio (NASDAQ:PACB) on Tuesday announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154 million, representing a year-over …

msn.com

$39
OFF

PacBio Announces Preliminary Fourth Quarter And Full Year Revenue

2 weeks from now

22 hours ago · Preliminary fourth quarter results: Preliminary, unaudited revenue for the fourth quarter of 2024 is expected to be approximately $39.2 million compared with $58.4 million in …

yahoo.com

$35
OFF

PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues

2 weeks from now

Jan 17, 2022 · The Zacks Consensus Estimate of $35.9 million remains below the preliminary figure. During the fourth quarter, PacBio confirmed placing a record 48 Sequel II/IIe systems, …

nasdaq.com

$39
OFF

PacBio Announces Preliminary Fourth Quarter And Full Year Revenue

2 weeks from now

22 hours ago · Preliminary, unaudited revenue for the fourth quarter of 2024 is expected to be approximately $39.2 million compared with $58.4 million in the prior-year period.

businessinsider.com

33%
OFF

PacBio Announces Preliminary Fourth Quarter And Full Year Revenue

2 weeks from now

1 day ago · The preliminary Q4 results reveal concerning trends for PacBio, with revenue declining 33% year-over-year to $39.2 million.Most notably, instrument revenue dropped …

stocktitan.net

$15
OFF

PacBio Announces Preliminary Fourth Quarter And Full Year

2 weeks from now

22 hours ago · Preliminary instrument revenue for the fourth quarter of 2024 is expected to be approximately $15.3 million, compared with $35.1 million for the fourth quarter of 2023. …

globenewswire.com

$5
OFF

PacBio Announces Preliminary Fourth Quarter And Full Year Revenue

2 weeks from now

19 hours ago · Preliminary service and other revenue for the fourth quarter of 2024 is expected to be approximately $5.1 million, compared with $4.4 million for the fourth quarter of 2023.

finanznachrichten.de

FAQs about PacBio Announces Preliminary Fourth Quarter and Full Year Revenue Coupon?

How did PacBio perform in Q4 2024?

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154.0 million representing a year-over-year decline of 33% and 23%, respectively. ...

What was PacBio's fourth quarter revenue?

PacBio reported preliminary, unaudited revenue of approximately $58.4 million for its fourth quarter ended December 31, 2023. Preliminary instrument revenue for the fourth quarter of 2023 is expected to be approximately $35.1 million, compared with $6.1 million for the fourth quarter of 2022. ...

How many PacBio sequencers were shipped in 2023?

Ships a record number of PacBio sequencers in 2023, including 173 Revio™ systems, and announces record fourth quarter preliminary consumable revenue of $18.9 million as demand for long-read sequencing grows and increased capacity from the Revio system drives sample elasticity ...

How much cash will PacBio have in 2024?

Total preliminary unrestricted cash, cash equivalents, and investments balance as of December 31, 2024, is expected to be approximately $390 million. PacBio is scheduled to present at the 43 rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 4:30 p.m. Pacific Time. ...

What is PacBio's revenue target for 2026?

PacBio continues to target compound annual revenue growth of 40% to 50% through 2026 based on a 2022 revenue base of $128.3 million, representing a 2026 revenue target of over $500 million. PacBio expects to share 2024 guidance on its fourth-quarter earnings conference call in February 2024. About PacBio ...

Why was 2023 a landmark year for PacBio?

"2023 was a landmark year for PacBio. The launch of the Revio system for scalable, accurate, long read sequencing and Onso, a short read sequencer with groundbreaking accuracy enabled PacBio to reach more customers than ever before and, in the process, achieve record financial results," said Christian Henry, President and CEO of PacBio. ...